Inmune Bio (INMB) Assets Average (2019 - 2026)
Inmune Bio (INMB) posted Assets Average of $29.1 million for Q1 2026, down 11.47% sequentially from $32.9 million in Q4 2025, and down 24.81% YoY from $38.7 million in Q1 2025.
Inmune Bio (INMB) Assets Average (2019 - 2026) Analysis & Trends
Inmune Bio has reported Assets Average for 8 years, with the latest figure at $29.1 million in Q1 2026.
- Quarterly Assets Average fell 24.81% year-over-year to $29.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (down 24.81% YoY) and the FY2025 annual result came in at $36.0 million, down 25.53% from the prior year.
- Assets Average eased to $29.1 million in Q1 2026 per INMB's latest filing, from $32.9 million in the prior quarter.
- Over five years, Assets Average peaked at $97.1 million in Q1 2022 and troughed at $29.1 million in Q1 2026.
- A 5-year average of $62.2 million and a median of $59.8 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average surged 82.39% in 2022, then plunged 33.34% in 2024.
- Over 5 years, Assets Average stood at $82.8 million in 2022, then decreased by 27.72% to $59.8 million in 2023, then fell by 22.85% to $46.2 million in 2024, then decreased by 28.84% to $32.9 million in 2025, then dropped by 11.47% to $29.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $29.1 million, $32.9 million, and $38.7 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 19.82 Bn |
| 10 | Inmune Bio | 61.32 Mn | 42.91 Mn | - | 26.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.33 Mn |
| Mar 31, 2026 | 29.08 Mn |
| Dec 31, 2025 | 32.85 Mn |
| Mar 31, 2025 | 38.68 Mn |
| Dec 31, 2024 | 46.17 Mn |
| Sep 30, 2024 | 52.62 Mn |
| Jun 30, 2024 | 49.64 Mn |
| Mar 31, 2024 | 51.92 Mn |
| Dec 31, 2023 | 59.85 Mn |
| Sep 30, 2023 | 66.21 Mn |
| Jun 30, 2023 | 71.85 Mn |
| Mar 31, 2023 | 77.89 Mn |
| Dec 31, 2022 | 82.80 Mn |
| Sep 30, 2022 | 85.80 Mn |
| Jun 30, 2022 | 91.08 Mn |
| Mar 31, 2022 | 97.15 Mn |
| Dec 31, 2021 | 103.81 Mn |
| Sep 30, 2021 | 84.19 Mn |
| Jun 30, 2021 | 63.29 Mn |
| Mar 31, 2021 | 53.27 Mn |